Pharma BD Deal Intelligence
"Valeant Pharmaceuticals has snapped up another dermatology specialist in its ongoing quest to build its business in the field" — factual framing within…
Trade coverage relaying the company framing that the deal would 'solidify our position as a leader in dermatology,' presented as a strategic portfolio…
The FTC required Valeant and PreCision to sell or relinquish rights to PreCision's branded single-agent topical tretinoins and generic Retin-A to settle…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Valeant closed its acquisition of privately held PreCision Dermatology for $475M cash, expanding its dermatology franchise (already enlarged by Bausch + Lomb). Notable as one of Valeant's bolt-ons during the Allergan hostile-bid period.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Valeant Pharmaceuticals International, Inc. / PreCision Dermatology, Inc. (this deal) | 2014 | $475M | 23 |
| Valeant Pharmaceuticals International, Inc. / Dow Pharmaceutical Sciences, Inc. | 2009 | $285M | 66 |
| Valeant Pharmaceuticals International, Inc. / iNova Pharmaceuticals | 2011 | $700M | 63 |
| Valeant Pharmaceuticals International, Inc. / Xcel Pharmaceuticals, Inc. | 2005 | $280M | 42 |
| Valeant Pharmaceuticals International, Inc. / Dermik Laboratories (Sanofi dermatology unit) | 2011 | $425M | 36 |
| Valeant Pharmaceuticals International, Inc. / Bausch + Lomb | 2013 | $8.7B | 36 |
| Valeant Pharmaceuticals International, Inc. / Medicis Pharmaceutical Corporation | 2012 | $2.6B | 33 |
← Browse all deals · How we score deals
More: 2014 deals · Valeant Pharmaceuticals International, Inc. deals · Dermatology deals